Breaking new grounds: YUMAB GmbH at Science Campus Braunschweig-Süd
Biotech pioneer moves antibody discovery platform and cooperates with the Helmholtz Centre for Infection Research
YUMAB, a privately-held German biotechnology company that started out five years ago as a spin-off from the Technical University of Braunschweig (TUBS) to provide tailored solutions for human antibody discovery and development, has expanded considerably and now moved its headquarter to the Science Campus Braunschweig-Süd to satisfy the need for more space, a superior infrastructure, and high-level scientific partnering.
Based on the profound expertise of YUMAB’s four founders Stefan Dübel, André Frenzel, Michael Hust, and Thomas Schirrmann in antibody phage display, the company was founded in 2012 with the goal to meet the demand for fully human antibodies in life science research and pharmaceutical development. Since then, the founders with each up to 28 years of research experience have built a unique technology platform for the generation of advanced recombinant fully human antibodies that cover a broad application spectrum, including therapeutics, diagnostics, and vaccines. In fee-for-service solutions and attractive flexible licensing options, YUMAB provides rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering, and custom-made antibodies to difficult targets.
With Thomas Schirrmann as CEO, YUMAB started as one-man company but has quickly evolved to a solid 20+ employee corporation that operates globally. After five years, YUMAB is already a driver of the general trend in immunotherapy toward the use of fully human antibodies in therapeutic applications. Building on this successful development, YUMAB is now reaching out for the U.S. market and has opened its first subsidiary – YUMAB Inc. – last year in Atlanta, Georgia.
YUMAB will benefit from the scientific expertise as well as the sophisticated research facilities and technologies available on-site which represent the ideal environment for the development of novel human antibodies for the treatment of infectious diseases and other therapeutic indications.
To further enable sustainable growth, YUMAB has now relocated its headquarter into larger accommodations of the renowned Helmholtz Centre for Infection Research (HZI) at the Science Campus Braunschweig-Süd, which is the largest academic research institute in Germany with focus on infectious diseases. The Scientific Director of the HZI - Dirk Heinz - considers the relocation of YUMAB as a true win-win situation for all partners with ample possibilities for new collaborations: "The easy access to specific human antibodies through YUMAB facilitates novel therapeutic approaches towards fighting antibiotic-resistant pathogens that pose an enormous threat in modern medicine.” With his decision to move on campus, Thomas Schirrmann is convinced: “YUMAB will benefit from the scientific expertise as well as the sophisticated research facilities and technologies available on-site which represent the ideal environment for the development of novel human antibodies for the treatment of infectious diseases and other therapeutic indications.”
The YUMAB−Helmholtz cooperation will be settled on April 10th and Schirrmann is looking forward: “After five successful years, we are excited to write the next chapter of innovative antibody technologies at the Science Campus Braunschweig-Süd.”
YUMAB GmbH is a German biotechnology company founded in 2012 by scientists of the University of Braunschweig. YUMAB provides technologies, contract research, and services for the discovery and development of fully human antibodies for all therapeutic fields. In little more than five years, the company has become a global player in human monoclonal antibody development and drives the general trend in the immunotherapy space toward the use of fully human antibodies for therapeutic applications. Growing steadily with now over 20 employees, YUMAB has relocated its headquarters to the Science Campus Braunschweig-Süd at the beginning of 2018.